Volume 74, Issue 2, Pages (August 2018)

Slides:

Advertisements

Similar presentations

Volume 69, Issue 5, Pages (May 2016)

Advertisements

Volume 68, Issue 6, Pages (December 2015)

The PSA Era is not Over for Prostate Cancer

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 58, Issue 2, Pages (August 2010)

Volume 27, Issue 4, Pages (December 2016)

Maurizio Brausi, Federica Rizzi, Saverio Bettuzzi European Urology

Testosterone Therapy in Men With Prostate Cancer

Volume 68, Issue 6, Pages e129-e131 (December 2015)

Volume 53, Issue 4, Pages (April 2008)

Volume 70, Issue 6, Pages (December 2016)

Volume 60, Issue 2, Pages (August 2011)

Volume 199, Issue 1, Pages (January 2018)

Volume 74, Issue 2, Pages (August 2018)

Volume 51, Issue 4, Pages (April 2007)

Volume 52, Issue 4, Pages (October 2007)

Volume 63, Issue 1, Pages (January 2013)

Volume 65, Issue 5, Pages (May 2014)

Volume 66, Issue 2, Pages (August 2014)

Volume 74, Issue 1, Pages (July 2018)

Volume 65, Issue 3, Pages (March 2014)

Elizabeth K. Bancroft, Rosalind A. Eeles

Volume 65, Issue 1, Pages (January 2014)

Volume 68, Issue 5, Pages (November 2015)

Volume 71, Issue 1, Pages 1-3 (January 2017)

Volume 61, Issue 4, Pages (April 2012)

Volume 53, Issue 4, Pages (April 2008)

Prostate Cancer Detection: A View of the Future

Volume 70, Issue 5, Pages (November 2016)

Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance Adam B. Weiner, Ruth Etzioni, Scott E. Eggener

Volume 67, Issue 3, Pages (March 2015)

Volume 66, Issue 3, Pages (September 2014)

Volume 70, Issue 5, Pages (November 2016)

Laurent Boccon-Gibod European Urology Supplements

Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients Timo F.W. Soeterik,

Luis Martínez-Piñeiro European Urology Supplements

The PSA Era is not Over for Prostate Cancer

Volume 53, Issue 2, Pages (February 2008)

Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers Pasquale Rescigno, David Lorente, David Dolling, Roberta Ferraldeschi, Daniel.

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 53, Issue 4, Pages (April 2008)

Volume 72, Issue 1, Pages (July 2017)

Volume 66, Issue 2, Pages (August 2014)

Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study Stephen H. Culp, Paul.

Volume 68, Issue 4, Pages (October 2015)

Is It Necessary to Detect All Prostate Cancers in Men with Serum PSA Levels

Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.

Two-years Postradiotherapy Biopsies: Lessons from MRC RT01 Trial

Volume 71, Issue 2, Pages (February 2017)

Volume 50, Issue 5, Pages (November 2006)

Selma Masic, Janet E. Cowan, Samuel L. Washington, Hao G

Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography Andrew.

Volume 73, Issue 5, Pages (May 2018)

Volume 71, Issue 6, Pages (June 2017)

Volume 55, Issue 6, Pages (June 2009)

Volume 71, Issue 5, Pages (May 2017)

Maurizio Brausi, Federica Rizzi, Saverio Bettuzzi European Urology

The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.

Volume 74, Issue 3, Pages (September 2018)

Volume 70, Issue 1, Pages (July 2016)

Volume 71, Issue 4, Pages (April 2017)

Volume 75, Issue 3, Pages (March 2019)

Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders

Volume 74, Issue 6, Pages (December 2018)

Volume 69, Issue 5, Pages (May 2016)

Edith Canby-Hagino, Javier Hernandez, Timothy C. Brand, Ian Thompson

Ian W. Mills, Anna Crossland, Anup Patel, Henrikas Ramonas

European Urology Oncology

Kaplan-Meier curves for PFS (panel A) and OS (panel B) of patients with mTCC receiving an anti-EGFR based therapy. mTCC, metastatic transverse colon cancer;

Kaplan-Meier (K-M) curves of progression-free survival (PFS) in 54 patients with metastatic gastric cancer treated with RAD001. Kaplan-Meier (K-M) curves.

Presentation transcript:

Volume 74, Issue 2, Pages 218-225 (August 2018) Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration- resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide Emmanuel S. Antonarakis, Changxue Lu, Brandon Luber, Chao Liang, Hao Wang, Yan Chen, John L. Silberstein, Danilo Piana, Zhao Lai, Yidong Chen, William B. Isaacs, Jun Luo European Urology Volume 74, Issue 2, Pages 218-225 (August 2018) DOI: 10.1016/j.eururo.2018.01.035 Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 1 (A) Waterfall plot showing best PSA response in patients with and without (any) germline mutations. (B–D) Kaplan-Meier curves showing (B) PSA-PFS, (C) PFS, and (D) OS in patients with and without (any) germline mutations. Kaplan-Meier curves were truncated at 24 mo for PSA-PFS and PFS and at 48 mo for OS. PSA=prostate-specific antigen; PFS=progression-free survival; OS=overall survival. European Urology 2018 74, 218-225DOI: (10.1016/j.eururo.2018.01.035) Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 2 (A) Waterfall plot showing best PSA response in patients with and without germline BRCA/ATM mutations. (B–D) Kaplan-Meier curves showing (B) PSA-PFS, (C) PFS, and (D) OS in patients with and without germline BRCA/ATM mutations. Kaplan-Meier curves were truncated at 24 mo for PSA-PFS and PFS and at 48 mo for OS. PSA=prostate-specific antigen; PFS=progression-free survival; OS=overall survival. European Urology 2018 74, 218-225DOI: (10.1016/j.eururo.2018.01.035) Copyright © 2018 European Association of Urology Terms and Conditions